This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintide version B, and which treatment participants receive is decided by chance. Participants will be in this clinical study for about 6 months.
Aged 18-64 years (both inclusive) at the time of signing informed consent
Body mass index (BMI) between 27.0 and 34.9 kilograms per square metre (kg/m²) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Previous participation in study(s) with an amylin analogue. Participation is defined as randomisation.
Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Novo Nordisk A/S
Lead sponsor